Vancomycin

證據等級: L5

預測適應症: 10 個

Vancomycin: From Gram-Positive Bacterial Infections to Streptococcal Pneumonia

Note on indication selection: This evidence pack (TW-DB00512-multi) evaluated 10 TxGNN-predicted indications for vancomycin. Nine of them (ranked #1–#8, #10 by raw TxGNN score) were explicitly flagged in the source data's own repurposing_rationale as mechanistically implausible or unsupported by any efficacy evidence — several are outright judged "false positives" by the evidence-collection pipeline itself. Only streptococcal pneumonia (rank #9) carries an L1 evidence level and a Proceed with Guardrails recommendation. This report therefore centers on streptococcal pneumonia as the only actionable candidate, and summarizes the other 9 for transparency below.

One-Sentence Summary

Vancomycin is a glycopeptide antibiotic historically used for serious Gram-positive bacterial infections (original indication text is a data gap in this pack, as the drug is not yet marketed in New Zealand). TxGNN separately assigned it a 99.60% prediction score for Streptococcal Pneumonia, and unlike most of the model's other top hits for this drug, this one is backed by 3 clinical trials and 20 publications, including a treatment meta-analysis and randomized comparisons — making it a genuine evidence-reinforcement case rather than a novel biological hypothesis.

Quick Overview

Item	Content
Original Indication	Not available from regulatory sources (data gap; not marketed in New Zealand). Based on general drug identity referenced within this evidence pack's own trial data, vancomycin is a glycopeptide antibiotic used for serious Gram-positive infections.
Predicted New Indication	Streptococcal Pneumonia
TxGNN Prediction Score	99.60% (rank 3867 among all disease predictions for this drug)
Evidence Level	L1
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Other TxGNN-Predicted Indications Screened (for transparency)

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation	Screening Note
1	Diffuse scleroderma	99.92%	L5	Hold	No mechanistic link; sole literature hit is an unrelated sepsis case report — likely false positive
2	Paratyphoid fever	99.85%	L4	Hold	Gram-negative pathogen; vancomycin lacks activity; no efficacy evidence
3	Salmonellosis	99.81%	L4	Hold	Gram-negative pathogen; 20 literature hits are epidemiology/surveillance, none evaluate treatment efficacy
4	Congenital analbuminemia	99.79%	L5	Hold	No mechanistic link, zero evidence
5	Polyclonal hyperviscosity syndrome	99.79%	L5	Hold	No mechanistic link, zero evidence
6	Hyperamylasemia	99.79%	L5	Hold	No mechanistic link, zero evidence
7	Typhoid fever	99.75%	L4	Hold	Gram-negative pathogen; only a single unrelated case report supports use
8	Blood group incompatibility	99.63%	L5	Hold	No mechanistic link; immunohematologic condition unrelated to antimicrobial action
9	Streptococcal pneumonia	99.60%	L1	Proceed with Guardrails	Featured below — real mechanistic and clinical support
10	Premalignant hematological system disease	99.54%	L5	Hold	No mechanistic link, zero evidence

This pattern — a cluster of very high but clinically implausible TxGNN scores alongside one biologically coherent hit — suggests the model's raw ranking is not reliable on its own for this drug and should always be triaged against mechanism and evidence before being acted on.

Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action text was not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on well-established pharmacology referenced within the evidence pack itself (e.g., trial NCT05395520 describes it as "a glycopeptide antibiotic… prescribed… due to its broad gram-positive coverage"), vancomycin inhibits bacterial cell wall peptidoglycan synthesis, which is bactericidal against Gram-positive organisms.

Streptococcus pneumoniae is a Gram-positive coccus, so this mechanism is directly applicable — unlike most of the other TxGNN hits above, which target Gram-negative organisms (Salmonella spp.) that vancomycin's large molecular size cannot penetrate, or conditions with no plausible pharmacological connection at all.

Importantly, the underlying evidence pack's own rationale notes this is not a novel repurposing hypothesis but a reinforcement of an already-recognized clinical use: vancomycin is a standard or alternative therapy for penicillin-resistant pneumococcus or for severe community-acquired pneumonia where concurrent MRSA is suspected. The TxGNN signal here is best read as the model correctly recovering an existing evidence-backed use rather than surfacing something new.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05395520	N/A	Unknown	146	Evaluates whether AUC-based therapeutic monitoring of IV vancomycin is appropriate beyond serious MRSA infections, implicitly covering broader Gram-positive infection populations including pneumonia; direct dose–efficacy evidence for the drug itself (relevance grade A), though status is unverified.
NCT04464291	N/A	Completed	500	Epidemiological survey of circulating S. pneumoniae serotypes in Russia; provides disease background but does not evaluate vancomycin treatment (relevance grade C).
NCT02538211	N/A	Completed	63	Studies intestinal microbiome effects on rotavirus vaccine response; not directly related to vancomycin treatment of pneumonia (relevance grade C).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21211409	2010	Meta-analysis	Chinese Journal of Tuberculosis and Respiratory Diseases	Meta-analysis of RCTs comparing linezolid vs. vancomycin for pneumonia caused by Gram-positive cocci, evaluating efficacy and safety of vancomycin as an active comparator.
10712318	2000	RCT	American Journal of Respiratory and Critical Care Medicine	Prospective randomized, multicenter trial (n=298) comparing quinupristin/dalfopristin vs. vancomycin for Gram-positive nosocomial pneumonia.
26664260	2015	Retrospective Study	International Journal of Medical Sciences	Retrospective analysis found no resistance to penicillin, cefuroxime, cefotaxime, or vancomycin among pneumococcal pneumonia isolates.
3630711	1987	Preclinical (Animal Model)	Acta Pathologica, Microbiologica, et Immunologica Scandinavica	Mouse-protection model shows vancomycin achieves the highest bactericidal rate relative to MIC against S. pneumoniae type 3 among tested antibiotics.
36028454	2022	Cohort/Surveillance	Indian Journal of Medical Microbiology	Surveillance of antibiotic resistance rates and penicillin/vancomycin MIC distribution in streptococcal pneumonia patients, 2013–2019.
27161775	2016	Cohort	Clinical Infectious Diseases	Characterizes prevalence and clinical features of S. aureus community-acquired pneumonia, informing empiric Gram-positive coverage (incl. vancomycin) decisions.
9404765	1997	Review	Chest	Discusses declining penicillin use for pneumococcal pneumonia amid resistant strains, and concerns about vancomycin overuse as an alternative.
16341681	2005	Review	European Journal of Clinical Microbiology & Infectious Diseases	Reviews antibiotic management of ventilator-associated pneumonia due to resistant Gram-positive bacteria, with vancomycin as a mainstay option.
16735146	2006	Review	American Journal of Medicine	Reviews antimicrobial resistance among Gram-positive bacteria (MRSA, VRE) and vancomycin's central clinical role.
27929242	2016	Review	American Family Physician	General review of community-acquired pneumonia diagnosis and severity-guided antibiotic selection.

New Zealand Market Information

Vancomycin currently has no market authorizations on file in New Zealand (market status: Not Marketed; 0 total licenses). No product-level licensing table is available from this evidence pack.

Safety Considerations

No structured regulatory safety data (key warnings, contraindications, or drug interactions) is currently available for vancomycin in this evidence pack — this is logged as a Blocking-severity data gap (DG001) pending retrieval of the official package insert. Formal drug-interaction database lookup also returned no results.

For general context only (not a formal safety assessment): one referenced trial (NCT05395520) notes that intravenous vancomycin carries known risks of nephrotoxicity, ototoxicity, and hypersensitivity reactions, and that AUC-guided therapeutic drug monitoring is increasingly used clinically to manage these risks.

Please refer to the official package insert once available for authoritative safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for streptococcal pneumonia specifically — all other 9 TxGNN-predicted indications for vancomycin in this pack remain at Hold)

Rationale: Streptococcal pneumonia is the only one of vancomycin's 10 top TxGNN predictions with a coherent mechanism (Gram-positive cell wall synthesis inhibition) and real supporting clinical literature, including a treatment meta-analysis and a randomized comparative trial. However, this represents evidence reinforcement of an already-recognized clinical use (e.g., penicillin-resistant pneumococcus, suspected concurrent MRSA) rather than a novel repurposing signal, and two Blocking/High-severity data gaps (official warnings/contraindications, and confirmed MOA) remain unresolved.

To proceed, the following is needed:

TFDA/Medsafe package insert data (warnings, contraindications) — currently Blocking data gap (DG001)
Confirmed mechanism-of-action detail from DrugBank — currently High-severity data gap (DG002)
Confirmation of New Zealand regulatory/market-authorization pathway, since the drug is currently unmarketed there
Formal drug–drug interaction data
Given that 9 of 10 top TxGNN hits for vancomycin in this pack were assessed as mechanistically implausible, any further TxGNN signals for this drug should be manually triaged for biological plausibility before entering the automated evidence pipeline
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.